FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study - The
Avastin® (bevacizumab) Clinical Trials | MRCC Treatment
Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with (“pseudo-randomized”) treatment allocation by the health insurance provider | SpringerLink
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study - ScienceDirect
Overall survival and time to treatment failure for patients eligible... | Download Scientific Diagram
Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3 | British Journal of
Avastin® (bevacizumab) Clinical Trials | MCRC Treatment
IMpower150 Clinical Trial Results | TECENTRIQ® (atezolizumab)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer | NEJM
Figure 3 from Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. | Semantic Scholar
Landmark OS for HCC, updated IMbrave150 data - Medical Conferences
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial - The Lancet Respiratory
When more is better: bevacizumab treatment for patients with ovarian cancer
Avastin® (bevacizumab) Clinical Trials for Ovarian Cancer | HCP
Avastin® (bevacizumab) Clinical Trials | CC Treatment
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis | BMC Cancer | Full Text
Cancers | Free Full-Text | Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project
Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study | International Journal of Gynecologic Cancer
Overall survival for patients randomized to receive (A) bevacizumab (n... | Download Scientific Diagram
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer - Medical Conferences
Bevacizumab Progression-free Survival Benefit Upheld in AVEREL Trial - The ASCO Post
